40-31 FDA Moves to Regulate Lab-Developed Tests

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA Moves to Regulate Lab-Developed TestsBy Paul Goldberg

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe


Patients with metastatic non-small cell lung cancer who are matched to targeted therapy live longer when liquid biopsies are used to detect genomic alterations in circulating tumor DNA that aren’t picked up by tissue sequencing, according to a study published Nov. 10 in Nature Medicine.
Editor & Publisher